Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design.
LanguageEnglish
Pages448-458
Number of pages11
JournalTrends in Biotechnology
Volume31
Issue number8
DOIs
Publication statusPublished - 14 Jun 2013

Fingerprint

Agglomeration
Technology
Proteins
Genetic engineering
Monoclonal antibodies
Biotechnology
Product design
Recombinant DNA
Innovation
Monoclonal Antibodies
Throughput
Artifacts
Therapeutics

Keywords

  • aggregation
  • biopharmaceuticals
  • manufacture
  • product development
  • quality by design
  • biopharmaceutical aggregation

Cite this

@article{096d4804cfe047acbf331d24380edc76,
title = "Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation",
abstract = "Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design.",
keywords = "aggregation, biopharmaceuticals, manufacture, product development, quality by design, biopharmaceutical aggregation",
author = "Zahra Hamrang and Nicholas Rattray and Alain Pluen",
year = "2013",
month = "6",
day = "14",
doi = "10.1016/j.tibtech.2013.05.004",
language = "English",
volume = "31",
pages = "448--458",
journal = "Trends in Biotechnology",
issn = "0167-7799",
number = "8",

}

Proteins behaving badly : emerging technologies in profiling biopharmaceutical aggregation. / Hamrang, Zahra; Rattray, Nicholas; Pluen, Alain.

In: Trends in Biotechnology, Vol. 31, No. 8, 14.06.2013, p. 448-458.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Proteins behaving badly

T2 - Trends in Biotechnology

AU - Hamrang, Zahra

AU - Rattray, Nicholas

AU - Pluen, Alain

PY - 2013/6/14

Y1 - 2013/6/14

N2 - Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design.

AB - Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design.

KW - aggregation

KW - biopharmaceuticals

KW - manufacture

KW - product development

KW - quality by design

KW - biopharmaceutical aggregation

U2 - 10.1016/j.tibtech.2013.05.004

DO - 10.1016/j.tibtech.2013.05.004

M3 - Review article

VL - 31

SP - 448

EP - 458

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

IS - 8

ER -